Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Bristol Will Use Partners To Maintain Primary Care Presence

This article was originally published in The Pink Sheet Daily

Executive Summary

Company is using a "different model," not "exiting," primary care, CEO says. Deal with Merck for diabetes compound is example of how Bristol will use partnerships going forward.

You may also be interested in...



New Targets For Biologic Rheumatoid Arthritis Therapy Featured At ACR Meeting

Bristol’s Phase III candidate abatacept inhibits cytokine production, while marketed biologic agents for rheumatoid arthritis inhibit the specific cytokines tumor necrosis factor and interleukin-1. Phase II data on monoclonal antibodies presented at American College of Rheumatology includes Roche’s anti-IL-6 MRA and Amgen’s anti-IL-15 AMG-714.

New Targets For Biologic Rheumatoid Arthritis Therapy Featured At ACR Meeting

Bristol’s Phase III candidate abatacept inhibits cytokine production, while marketed biologic agents for rheumatoid arthritis inhibit the specific cytokines tumor necrosis factor and interleukin-1. Phase II data on monoclonal antibodies presented at American College of Rheumatology includes Roche’s anti-IL-6 MRA and Amgen’s anti-IL-15 AMG-714.

Primary Care Sales Force Downsizing Will Continue, Bristol Says

Bristol-Myers Squibb expects additional downsizing of its primary care sales force as it shifts its product portfolio to specialty care, Exec VP Donald Hayden told analysts July 29

Topics

UsernamePublicRestriction

Register

LL1133951

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel